Komori
Financial results presentation4892Cyfuse Biomedical K.K.Pharmaceuticals

Financial Results Briefing Materials for the Second Quarter of the Fiscal Year Ending December 2026

In the first half, sales from contract services and existing devices increased, bringing net sales to 3.5 times the year-earlier level. Operating loss narrowed, while ordinary loss and interim net loss widened due mainly to a decline in non-operating income. Progress was also made in clinical trials for the regenerative medicine pipeline, the launch of new products, and partnerships and joint development.

Worth reading
41Recurring
Scored from 5 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
254.6
% (year-on-year change in revenue)
Wording
Conditional
How definitive the wording is.

Contents of this document

Financial results presentationSecond quarter of the fiscal year ending December 20265 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥104,321 thousand+254.6%
Operating profit¥-417,507 thousand
Ordinary income¥-433,317 thousand
Net income¥-434,588 thousand
Selling, general and administrative expenses¥482,307 thousand
Full-year earnings forecast
Net Sales
¥278 million
Operating profit
¥-1,081 million
Ordinary income
¥-1,056 million
Net income
¥-1,059 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Revenue increase¥74,901 thousand
  • Increase in costs of sales¥24,766 thousand
  • Increase in gross profit¥50,135 thousand
  • Decrease in selling, general and administrative expenses¥-3,605 thousand
  • Improvement in operating loss¥53,741 thousand
  • Decrease in non-operating income¥-72,522 thousand
  • Increase in non-operating expenses¥13,286 thousand
New initiatives
  • Launch of an investigator-initiated clinical trial for allogeneic peripheral nerve regeneration
  • Submission of a clinical trial notification for osteochondral regeneration, with the clinical trial scheduled to begin in 4Q 2026
  • Launch of sales of the new Human 3D Mini Liver®/Disease Model
  • Launch of sales of the new CAP (foldable compact dispensing machine)
  • Development and launch of sales of a recirculating culture pump
  • Launch of a business and capital alliance and collaboration with KURARAY CO.,LTD.
  • Joint development of commercial production and large-scale cell culture technologies with 日本精工, KURARAY CO.,LTD., ZACROS, 千代田化工建設 and others
  • Joint development of periodontal tissue regeneration therapy with Hiroshima University
Key KPIsA metric the company considers important as a management benchmark.
  • Number of regenerative medicine products approved in Japan27 Products
  • Number of distributors in the drug discovery support sector5 companies
  • Number of clinical trial cases for allogeneic peripheral nerve regeneration3 Cases scheduled for transplantation
  • Number of employees23 people
Market Size / Share
  • Patients with traumatic peripheral nerve injuries (United States)140 10,000 people
  • Patients with traumatic peripheral nerve injuries (Japan)Approximately 6.8 to 17
  • Patients receiving artificial nerve implants (United States)10 10,000 people
  • Patients receiving artificial nerve implants (Japan)1.5 10,000 people
  • Artificial nerve sales (United States)¥125 100 million
  • Artificial nerve sales (Japan)Approximately 30 to 50
  • Potential patients for osteochondral regeneration in Japan3,000 10,000 people
  • Diagnosed patients for osteochondral regeneration in Japan1,000 10,000 people
  • New patients eligible for cell-based artificial blood vessels in Japan1.5 10,000 people/year
  • Cell therapy manufacturing automation systems market (2033)74 US$100 million
Number of employees
Number of Employees23 people
As ofAs of the end of December 2025
Contents of this document
ItemDetails
Document typeFinancial results presentation
Fiscal Period CoveredSecond quarter of the fiscal year ending December 2026
Net Sales¥104,321 thousand (YoY +254.6%)
Operating profit¥-417,507 thousand
Ordinary income¥-433,317 thousand
Net income¥-434,588 thousand
Selling, general and administrative expenses¥482,307 thousand
Full-year earnings forecastNet Sales ¥278 million / Operating profit ¥-1,081 million / Ordinary income ¥-1,056 million / Net income ¥-1,059 million
Breakdown of Factors Affecting the ChangeFactors Revenue increase / Amount ¥74,901 thousand, Factors Increase in costs of sales / Amount ¥24,766 thousand, Factors Increase in gross profit / Amount ¥50,135 thousand, Factors Decrease in selling, general and administrative expenses / Amount ¥-3,605 thousand, Factors Improvement in operating loss / Amount ¥53,741 thousand, Factors Decrease in non-operating income / Amount ¥-72,522 thousand, Factors Increase in non-operating expenses / Amount ¥13,286 thousand
Key KPIsIndicator name Number of regenerative medicine products approved in Japan / Value 27 Products / Year on year against the same period last year Not disclosed, Indicator name Number of distributors in the drug discovery support sector / Value 5 companies / Year on year against the same period last year Not disclosed, Indicator name Number of clinical trial cases for allogeneic peripheral nerve regeneration / Value 3 Cases (scheduled for transplantation) / Year on year against the same period last year Not disclosed, Indicator name Number of employees / Value 23 people / Year on year against the same period last year Not disclosed
Number of employeesNumber of Employees 23 people / As of As of the end of December 2025 / Change during the period Not disclosed / Hiring plan Not disclosed
Market Size / ShareSubject Patients with traumatic peripheral nerve injuries (United States) / Value 140 10,000 people, Subject Patients with traumatic peripheral nerve injuries (Japan) / Value Approximately 6.8 to 17, Subject Patients receiving artificial nerve implants (United States) / Value 10 10,000 people, Subject Patients receiving artificial nerve implants (Japan) / Value 1.5 10,000 people, Subject Artificial nerve sales (United States) / Value ¥125 100 million, Subject Artificial nerve sales (Japan) / Value Approximately 30 to 50, Subject Potential patients for osteochondral regeneration in Japan / Value 3,000 10,000 people, Subject Diagnosed patients for osteochondral regeneration in Japan / Value 1,000 10,000 people, Subject New patients eligible for cell-based artificial blood vessels in Japan / Value 1.5 10,000 people/year, Subject Cell therapy manufacturing automation systems market (2033) / Value 74 US$100 million
New initiativesLaunch of an investigator-initiated clinical trial for allogeneic peripheral nerve regeneration, Submission of a clinical trial notification for osteochondral regeneration, with the clinical trial scheduled to begin in 4Q 2026, Launch of sales of the new Human 3D Mini Liver®/Disease Model, Launch of sales of the new CAP (foldable compact dispensing machine), Development and launch of sales of a recirculating culture pump, Launch of a business and capital alliance and collaboration with KURARAY CO.,LTD., Joint development of commercial production and large-scale cell culture technologies with 日本精工, KURARAY CO.,LTD., ZACROS, 千代田化工建設 and others, Joint development of periodontal tissue regeneration therapy with Hiroshima University
Items this document does not state (18)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company cited increased sales of contract services and existing devices, the launch of sales of the new Human 3D Mini Liver®/Disease Model and CAP products, and efficient development promoted through partnerships. Regarding operating loss, the company stated that it worked to reduce the loss while continuing planned upfront investment. The deterioration in ordinary loss was attributed to a decline in non-operating income and an increase in non-operating expenses.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Briefing Materials for the Second Quarter of the Fiscal Year Ending December 2026 | Cyfuse Biomedical K.K. (4892) timely disclosure | Komori